Analysts’ Weekly Ratings Updates for Ionis Pharmaceuticals (IONS)

A number of research firms have changed their ratings and price targets for Ionis Pharmaceuticals (NASDAQ: IONS):

• 4/15/2025 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
• 4/8/2025 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
• 4/7/2025 – Ionis Pharmaceuticals is now covered by analysts at HC Wainwright. They set a “buy” rating and a $45.00 price target on the stock.
• 4/7/2025 – Ionis Pharmaceuticals was upgraded by analysts at HC Wainwright to a “strong-buy” rating. They now have a $45.00 price target on the stock.
• 4/3/2025 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Guggenheim.
• 3/31/2025 – Ionis Pharmaceuticals is now covered by analysts at Redburn Atlantic. They set a “neutral” rating and a $39.00 price target on the stock.
• 3/24/2025 – Ionis Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $47.00 to $45.00. They now have a “neutral” rating on the stock.
• 3/18/2025 – Ionis Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.
• 3/11/2025 – Ionis Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $51.00 to $47.00. They now have a “neutral” rating on the stock.

Ionis Pharmaceuticals Trading Up 1.6 %

Shares of IONS stock opened at $29.57 on Friday. The stock has a market capitalization of $4.70 billion, a P/E ratio of -9.73 and a beta of 0.29. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $23.95 and a fifty-two week high of $52.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The company has a 50 day moving average price of $30.72 and a 200 day moving average price of $33.98.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The firm had revenue of $227.00 million during the quarter, compared to analyst estimates of $140.97 million. During the same period last year, the business posted $0.12 earnings per share. Ionis Pharmaceuticals’s revenue was down 30.2% compared to the same quarter last year. Equities research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Patrick R. O’neil sold 1,207 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $32.35, for a total value of $39,046.45. Following the sale, the executive vice president now directly owns 56,245 shares of the company’s stock, valued at approximately $1,819,525.75. This represents a 2.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Brett P. Monia sold 38,843 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $31.65, for a total transaction of $1,229,380.95. Following the completion of the sale, the chief executive officer now owns 180,683 shares in the company, valued at $5,718,616.95. The trade was a 17.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,167 shares of company stock worth $2,010,458. Company insiders own 2.71% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Capital World Investors lifted its stake in Ionis Pharmaceuticals by 46.5% during the fourth quarter. Capital World Investors now owns 11,465,413 shares of the company’s stock worth $400,831,000 after purchasing an additional 3,637,041 shares during the last quarter. Norges Bank purchased a new stake in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $59,948,000. Vanguard Group Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 9.4% in the 4th quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company’s stock valued at $575,880,000 after buying an additional 1,416,781 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Ionis Pharmaceuticals in the 4th quarter valued at $20,801,000. Finally, Orbimed Advisors LLC raised its stake in Ionis Pharmaceuticals by 21.2% during the 4th quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company’s stock worth $98,494,000 after acquiring an additional 492,900 shares in the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.